FDA Approves cutaquig for Pediatric PI (IMAGE)
Caption
Octapharma USA today announced the U.S. Food & Drug Administration (FDA) has approved cutaquig® [Immune globulin, Subcutaneous (Human)-hipp, 16.5% Solution] for the treatment of pediatric patients age 2 and older with primary humoral immunodeficiency (PI).
Credit
Octapharma USA
Usage Restrictions
No restrictions
License
Licensed content